Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Stock Information for Q32 Bio Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Q32 Bio Inc Com

Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
Leap Therapeutics Reports Third Quarter 2023 Financial Results
Leap Therapeutics to Participate at Upcoming Investor Conferences
Leap Therapeutics Reports Second Quarter 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.